Jared Gollob, Chief Medical Officer at Kymera Therapeutics ($KYMR), sold about $9.1 million worth of company shares across 18 open market transactions in the last 365 days, with the most recent on March 4, 2026. His total sales rank 1208th among 11,678 individual insiders, above the average of $8.6 million per seller and 6.4 transactions. Gollob made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Common Stock | 17650 | $0.00 | 127,642.0000 | 87,300,286 | 16.05% | 0.02% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Stock Option (Right to Buy) | 35300 | $0.00 | 35,300.0000 | 87,300,286 | 9999.99% | 0.04% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 447 | $86.62 | 117,134.0000 | 87,300,286 | 0.38% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1437 | $85.78 | 117,581.0000 | 87,300,286 | 1.21% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 2519 | $85.04 | 119,018.0000 | 87,300,286 | 2.07% | 0.00% |
| March 4, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 492 | $84.00 | 121,537.0000 | 87,300,286 | 0.40% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 3048 | $89.66 | 122,029.0000 | 87,300,286 | 2.44% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1055 | $88.50 | 125,077.0000 | 87,300,286 | 0.84% | 0.00% |
| March 2, 2026 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1510 | $87.75 | 126,132.0000 | 87,300,286 | 1.18% | 0.00% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 13759 | $87.37 | 145,540.0000 | 87,300,286 | 8.64% | 0.02% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 49307 | $0.00 | 34,083.0000 | 87,300,286 | 59.13% | 0.06% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1400 | $92.19 | 109,992.0000 | 87,300,286 | 1.26% | 0.00% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 3300 | $91.46 | 111,392.0000 | 87,300,286 | 2.88% | 0.00% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 8562 | $90.12 | 114,692.0000 | 87,300,286 | 6.95% | 0.01% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 3929 | $89.43 | 123,254.0000 | 87,300,286 | 3.09% | 0.00% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 18357 | $88.02 | 127,183.0000 | 87,300,286 | 12.61% | 0.02% |
| Dec. 8, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 49307 | $5.33 | 159,299.0000 | 87,300,286 | 44.83% | 0.06% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 22210 | $0.00 | 0.0000 | 87,300,286 | 100.00% | 0.03% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 28999 | $1.31 | 147,358.0000 | 87,300,286 | 24.50% | 0.03% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 22210 | $2.08 | 169,568.0000 | 87,300,286 | 15.07% | 0.03% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 29264 | $60.37 | 140,304.0000 | 87,300,286 | 17.26% | 0.03% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 8963 | $61.49 | 131,341.0000 | 87,300,286 | 6.39% | 0.01% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 14896 | $62.72 | 116,445.0000 | 87,300,286 | 11.34% | 0.02% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 6453 | $63.09 | 109,992.0000 | 87,300,286 | 5.54% | 0.01% |
| Oct. 15, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 28999 | $0.00 | 0.0000 | 87,300,286 | 100.00% | 0.03% |
| Oct. 13, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 3114 | $60.00 | 118,359.0000 | 87,300,286 | 2.56% | 0.00% |
| Oct. 13, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 800 | $0.00 | 28,999.0000 | 87,300,286 | 2.68% | 0.00% |
| Oct. 13, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 673 | $0.00 | 22,210.0000 | 87,300,286 | 2.94% | 0.00% |
| Oct. 13, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 800 | $1.31 | 120,800.0000 | 87,300,286 | 0.67% | 0.00% |
| Oct. 13, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 673 | $2.08 | 121,473.0000 | 87,300,286 | 0.56% | 0.00% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 4695 | $30.33 | 121,045.0000 | 75,043,991 | 3.73% | 0.01% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Common Stock | 30000 | $0.00 | 125,740.0000 | 75,043,991 | 31.33% | 0.04% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 75,043,991 | 9999.99% | 0.08% |
| March 3, 2025 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1045 | $31.00 | 120,000.0000 | 75,043,991 | 0.86% | 0.00% |
| July 15, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 16455 | $45.15 | 95,740.0000 | 58,365,499 | 14.67% | 0.03% |
| July 15, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 16455 | $2.08 | 112,195.0000 | 58,365,499 | 17.19% | 0.03% |
| July 16, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 23145 | $0.00 | 22,883.0000 | 58,365,499 | 50.28% | 0.04% |
| July 15, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 16455 | $0.00 | 46,028.0000 | 58,365,499 | 26.34% | 0.03% |
| July 16, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 9864 | $46.10 | 95,470.0000 | 58,365,499 | 9.36% | 0.02% |
| July 16, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 13281 | $45.59 | 105,604.0000 | 58,365,499 | 11.17% | 0.02% |
| July 16, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 23145 | $2.08 | 118,885.0000 | 58,365,499 | 24.17% | 0.04% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Common Stock | 24375 | $0.00 | 99,084.0000 | 58,365,499 | 32.63% | 0.04% |
| March 1, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Stock Option (Right to Buy) | 146250 | $0.00 | 146,250.0000 | 58,365,499 | 9999.99% | 0.25% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 216 | $43.26 | 95,740.0000 | 58,365,499 | 0.23% | 0.00% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1106 | $42.39 | 95,956.0000 | 58,365,499 | 1.14% | 0.00% |
| March 4, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 2022 | $41.41 | 97,062.0000 | 58,365,499 | 2.04% | 0.00% |
| Feb. 27, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 400 | $2.08 | 75,109.0000 | 58,365,499 | 0.54% | 0.00% |
| Feb. 27, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 400 | $0.00 | 62,483.0000 | 58,365,499 | 0.64% | 0.00% |
| Feb. 27, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 400 | $45.00 | 74,709.0000 | 58,365,499 | 0.53% | 0.00% |
| Feb. 9, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Stock Option (Right to Buy) | 46137 | $0.00 | 62,883.0000 | 58,365,499 | 42.32% | 0.08% |
| Feb. 9, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | M | Common Stock | 46137 | $2.08 | 120,846.0000 | 58,365,499 | 61.76% | 0.08% |
| Feb. 9, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 38739 | $35.39 | 82,107.0000 | 58,365,499 | 32.06% | 0.07% |
| Feb. 9, 2024 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 7398 | $36.09 | 74,709.0000 | 58,365,499 | 9.01% | 0.01% |
| March 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 1001 | $30.88 | 75,006.0000 | 53,933,229 | 1.32% | 0.00% |
| March 1, 2023 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 53,933,229 | 9999.99% | 0.21% |
| March 2, 2023 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | S | Common Stock | 297 | $31.40 | 74,709.0000 | 53,933,229 | 0.40% | 0.00% |
| March 1, 2023 | Kymera Therapeutics, Inc. | $KYMR | Gollob Jared | Chief Medical Officer | A | Common Stock | 18750 | $0.00 | 76,007.0000 | 53,933,229 | 32.75% | 0.03% |